Gilead Sciences names two new EVP's

28 July 2015

US biotech major Gilead Sciences (Nasdaq: GILD) on Tuesday named William Lee the executive vice president (EVP) for research, and Brett Pletcher the EVP and general counsel. Both Mr Lee and Mr Pletcher will join the company’s senior leadership committee.

Mr Lee joined Gilead in 1991 and has led the expansion of the company's research activities across a range of therapeutic areas, including liver diseases, hematology/oncology, inflammation and respiratory diseases and cardiovascular conditions. He reports to chief scientific officer Norbert Bischofberger. Prior to joining Gilead, Mr Lee worked at California Biotechnology and Syntex.

Chief scientific officer Mr Bischofberge, said: "Over the past nearly 25 years, Bill has helped Gilead bring multiple product candidates from early stage research into development. His contributions to the discovery and advancement of internal drug candidates and evaluation of external candidates for potential partnership have allowed Gilead to bring important new medicines to patients around the world."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK